SARS-CoV-2 peptide fragments can reassemble with dsRNA into proinflammatory complexes, amplifying immune responses.
These complexes trigger cytokine secretion in various cell types, mimicking severe COVID-19 inflammation.
“Here is the first randomized trial to show that an antiviral can prevent Long Covid.
In the PANORAMIC trial, people randomized to molnupiravir had less risk of Long Covid than people who received no antivirals
My comment in the link below. A short🧵”
Literally living WITH Covid.
The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID
ANTIVIRAL THERAPIES FOR PERSISTENT COVID/LONG COVID 83% SUCCESS 70 of 84 cases with the aggravating factor of immunosuppression
The types of treatment were grouped into: Prolonged Antiviral therapy Combination Antivirals Mixed therapy: Antiviral +Antibody
Mouse got sick from blood of Long Covid patients. Dutch researchers have published a study (preprint), 31. May 2024 : "Transfer of IgG from Long COVID patients induces symptomology in mice"